CA1250213A - Procedure for the photometric determination of the activated partial thromboplastin time and a reagent for this purpose - Google Patents
Procedure for the photometric determination of the activated partial thromboplastin time and a reagent for this purposeInfo
- Publication number
- CA1250213A CA1250213A CA000450594A CA450594A CA1250213A CA 1250213 A CA1250213 A CA 1250213A CA 000450594 A CA000450594 A CA 000450594A CA 450594 A CA450594 A CA 450594A CA 1250213 A CA1250213 A CA 1250213A
- Authority
- CA
- Canada
- Prior art keywords
- reagent
- procedure
- partial thromboplastin
- activated partial
- thromboplastin time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 22
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 title claims abstract description 9
- 108010000499 Thromboplastin Proteins 0.000 title claims abstract description 9
- 102000002262 Thromboplastin Human genes 0.000 title claims abstract description 9
- 239000003593 chromogenic compound Substances 0.000 claims abstract description 13
- 239000012190 activator Substances 0.000 claims description 10
- 108090000190 Thrombin Proteins 0.000 claims description 9
- 229960004072 thrombin Drugs 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 230000037361 pathway Effects 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 7
- 238000001994 activation Methods 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000003114 blood coagulation factor Substances 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 3
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 3
- 229920002079 Ellagic acid Polymers 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002852 ellagic acid Drugs 0.000 description 3
- 235000004132 ellagic acid Nutrition 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- KZZWQCKYLNIOBT-UHFFFAOYSA-N 5-amino-2-nitrobenzoic acid Chemical compound NC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 KZZWQCKYLNIOBT-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108090000113 Plasma Kallikrein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DJMUYABFXCIYSC-UHFFFAOYSA-N 1H-phosphole Chemical compound C=1C=CPC=1 DJMUYABFXCIYSC-UHFFFAOYSA-N 0.000 description 1
- NJXWZWXCHBNOOG-UHFFFAOYSA-N 3,3-diphenylpropyl(1-phenylethyl)azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(C)[NH2+]CCC(C=1C=CC=CC=1)C1=CC=CC=C1 NJXWZWXCHBNOOG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- -1 Toluenesulfonyl Tris Chemical compound 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- XRFXFAVKXJREHL-UHFFFAOYSA-N arsinine Chemical compound [As]1=CC=CC=C1 XRFXFAVKXJREHL-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QQVNCBCBFNWLJX-KCHLEUMXSA-N n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 QQVNCBCBFNWLJX-KCHLEUMXSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001026 thromboplastic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
- C12Q2337/10—Anilides
- C12Q2337/12—Para-Nitroanilides p-NA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Peptides Or Proteins (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Cephalosporin Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833311287 DE3311287A1 (de) | 1983-03-28 | 1983-03-28 | Verfahren zur fotometrischen bestimmung der aktivierten partiellen thromboplastinzeit und reagenz dazu |
| DEP3311287.8 | 1983-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1250213A true CA1250213A (en) | 1989-02-21 |
Family
ID=6194903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000450594A Expired CA1250213A (en) | 1983-03-28 | 1984-03-27 | Procedure for the photometric determination of the activated partial thromboplastin time and a reagent for this purpose |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0123883B1 (en, 2012) |
| JP (1) | JPS59187800A (en, 2012) |
| AT (1) | ATE67520T1 (en, 2012) |
| AU (1) | AU582534B2 (en, 2012) |
| CA (1) | CA1250213A (en, 2012) |
| DE (2) | DE3311287A1 (en, 2012) |
| DK (1) | DK162179C (en, 2012) |
| ES (1) | ES530983A0 (en, 2012) |
| GR (1) | GR81852B (en, 2012) |
| IE (1) | IE58463B1 (en, 2012) |
| IL (1) | IL71370A (en, 2012) |
| NO (1) | NO164443C (en, 2012) |
| NZ (1) | NZ207626A (en, 2012) |
| ZA (1) | ZA842240B (en, 2012) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448024B1 (en) | 2000-10-03 | 2002-09-10 | Roche Diagnostics Corporation | Method, reagent, cartridge, and device for determining fibrinogen |
| US6699718B1 (en) | 1999-09-03 | 2004-03-02 | Roche Diagnostics Corporation | Method, reagent and test cartridge for determining clotting time |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4158785A (en) * | 1984-03-26 | 1985-11-01 | International Health Services | A method of determining the clotting time of blood and particulate reagents therefor |
| GB8426004D0 (en) * | 1984-10-15 | 1984-11-21 | Ortho Diagnostic Systems Inc | Coagulation monitoring |
| DE3504405A1 (de) * | 1985-02-08 | 1986-08-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Bestimmung von prokallikrein |
| SE8702556D0 (sv) * | 1987-06-18 | 1987-06-18 | Kabivitrum Ab | Bestemning av vid proteolys aktiva komponenter |
| US4865984A (en) * | 1988-02-08 | 1989-09-12 | Mount Sinai School Of Medicine Of The City University Of New York | Dynamic continuous flow enzyme reactor |
| DE4006634A1 (de) * | 1990-03-03 | 1991-09-05 | Behringwerke Ag | Funktioneller test zur bestimmung der protein s-aktivitaet |
| JP3180824B2 (ja) * | 1991-08-30 | 2001-06-25 | シスメックス株式会社 | 血液凝固試薬 |
| AT402074B (de) * | 1993-04-30 | 1997-01-27 | Immuno Ag | Reagens zur bestimmung der aptt |
| EP0570356B1 (de) * | 1992-05-15 | 1999-02-17 | IMMUNO Aktiengesellschaft | Reagens zur Bestimmung der aktivierten partiellen Thromboplastinzeit (aPTT) |
| AT398983B (de) * | 1992-05-15 | 1995-02-27 | Immuno Ag | Reagens zur bestimmung der aptt |
| ES2131543T3 (es) * | 1993-06-30 | 1999-08-01 | Stiftung Fur Diagnostische For | Medicion del tiempo de tromboplastina parcial activado (aptt) en una reaccion de una sola etapa. |
| US5780255A (en) * | 1995-06-09 | 1998-07-14 | Instrumentation Laboratory, S.P.A. | Protein C pathway screening test |
| KR100710122B1 (ko) | 2001-05-09 | 2007-04-20 | 엑시스-시일드 에이에스에이 | 분석 시스템 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3486981A (en) * | 1965-03-15 | 1969-12-30 | Roy E Speck | Substances relating to testing of blood-coagulation |
| DE2915310A1 (de) * | 1979-04-14 | 1980-10-30 | Behringwerke Ag | Neues partielles thromboplastin und dessen verwendung |
| CA1161432A (en) * | 1980-02-12 | 1984-01-31 | Lars G. Svendsen | Tripeptide derivatives and their application in assaying enzymes |
| DE3244030A1 (de) * | 1982-11-27 | 1984-05-30 | Behringwerke Ag, 3550 Marburg | Chromogene verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4487060A (en) * | 1983-05-18 | 1984-12-11 | Glenayre Electronis, Ltd. | Railway brake pressure monitor |
-
1983
- 1983-03-28 DE DE19833311287 patent/DE3311287A1/de not_active Withdrawn
-
1984
- 1984-02-27 DK DK109084A patent/DK162179C/da active
- 1984-03-22 DE DE8484103163T patent/DE3485067D1/de not_active Expired - Lifetime
- 1984-03-22 AT AT84103163T patent/ATE67520T1/de not_active IP Right Cessation
- 1984-03-22 EP EP84103163A patent/EP0123883B1/de not_active Expired - Lifetime
- 1984-03-26 GR GR74205A patent/GR81852B/el unknown
- 1984-03-26 ES ES530983A patent/ES530983A0/es active Granted
- 1984-03-26 NZ NZ207626A patent/NZ207626A/en unknown
- 1984-03-27 CA CA000450594A patent/CA1250213A/en not_active Expired
- 1984-03-27 JP JP59057507A patent/JPS59187800A/ja active Granted
- 1984-03-27 AU AU26211/84A patent/AU582534B2/en not_active Ceased
- 1984-03-27 ZA ZA842240A patent/ZA842240B/xx unknown
- 1984-03-27 IE IE74384A patent/IE58463B1/en not_active IP Right Cessation
- 1984-03-27 IL IL71370A patent/IL71370A/xx not_active IP Right Cessation
- 1984-03-28 NO NO841231A patent/NO164443C/no unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699718B1 (en) | 1999-09-03 | 2004-03-02 | Roche Diagnostics Corporation | Method, reagent and test cartridge for determining clotting time |
| US6448024B1 (en) | 2000-10-03 | 2002-09-10 | Roche Diagnostics Corporation | Method, reagent, cartridge, and device for determining fibrinogen |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3311287A1 (de) | 1984-10-04 |
| ES8505115A1 (es) | 1985-05-01 |
| DK109084A (da) | 1984-09-29 |
| IL71370A (en) | 1989-06-30 |
| IL71370A0 (en) | 1984-06-29 |
| AU2621184A (en) | 1984-10-04 |
| DK162179C (da) | 1992-03-02 |
| ZA842240B (en) | 1984-10-31 |
| AU582534B2 (en) | 1989-04-06 |
| EP0123883B1 (de) | 1991-09-18 |
| DE3485067D1 (de) | 1991-10-24 |
| NO164443C (no) | 1990-10-03 |
| ES530983A0 (es) | 1985-05-01 |
| NZ207626A (en) | 1987-05-29 |
| JPH0365958B2 (en, 2012) | 1991-10-15 |
| ATE67520T1 (de) | 1991-10-15 |
| NO164443B (no) | 1990-06-25 |
| EP0123883A2 (de) | 1984-11-07 |
| JPS59187800A (ja) | 1984-10-24 |
| EP0123883A3 (en) | 1988-02-10 |
| IE840743L (en) | 1984-09-28 |
| IE58463B1 (en) | 1993-09-22 |
| NO841231L (no) | 1984-10-01 |
| DK109084D0 (da) | 1984-02-27 |
| DK162179B (da) | 1991-09-23 |
| GR81852B (en, 2012) | 1984-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1250213A (en) | Procedure for the photometric determination of the activated partial thromboplastin time and a reagent for this purpose | |
| CA1258221A (en) | Reagent for the determination of the prothrombin time | |
| US4849403A (en) | Protein C activator, methods of preparation and use thereof | |
| JP3469909B2 (ja) | フィブリノーゲン測定のための実用的テストおよび試薬 | |
| Kluft et al. | alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. | |
| Bertina et al. | Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants | |
| Ragni et al. | Bleeding and coagulation abnormalities in alcoholic cirrhotic liver disease | |
| US4510241A (en) | Peptide-type substrates useful in the quantitative determination of endotoxin | |
| EP1367135A1 (en) | Improved method for the assessment of thrombin formation in blood or plasma | |
| Hoffmann et al. | Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy. | |
| EP0074761B1 (en) | Peptide-type substrates useful in the quantitative determination of endotoxin | |
| Walenga et al. | Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions | |
| Friberger | Synthetic peptide substrate assays in coagulation and fibrinolysis and their application on automates | |
| JPS61185199A (ja) | 血漿中のプロカリクレインを光度測定する方法 | |
| AU652737B2 (en) | Functional assay for determining the protein S activity | |
| US5200322A (en) | Method for assaying protein C and measuring kit for the same | |
| Kato et al. | Automated fluorogenic methods for the evaluation of the extrinsic coagulation reactions in human plasma | |
| Mannhalter | Biochemical and functional properties of factor XI and prekallikrein | |
| Triplett et al. | New methods in coagulation | |
| Eckfeldt et al. | Automated assay for alpha 1-antitrypsin with N-alpha-benzoyl-DL-arginine-p-nitroanilide as trypsin substrate and standardized with p-nitrophenyl-p'-guanidinobenzoate as titrant for trypsin active sites. | |
| Nakamura et al. | A high-molecular-weight trypsinlike protease in the skin sites of delayed hypersensitivity in guinea pigs | |
| EP0260707B1 (en) | Method for assaying plasma protein and measuring kit for the same | |
| Bertina | Protein C activity and antigen | |
| JP3291784B2 (ja) | 血液凝固因子活性測定法 | |
| Tripodi et al. | A chromogenic assay of prothrombin compared with coagulation tests during anticoagulant therapy and liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |